No abstract

MLL-rearranged (MLL-r) infant Acute lymphoblastic leukemia (ALL) is an aggressive leukemia with poor prognosis and poor response to conventional chemotherapy. Inotuzumab Ozogamicin (InO) is approved to treat relapsed ALL, typically as a bridge to more curative therapy. Here we present a case of prolonged MRD negative remission using Inotuzumab, in a patient with heavily treated, multiple relapsed, MLL-r infant ALL. InO should be considered as an alternative therapy for relapsed/refractory CD22+ infant ALL, either as a bridge to curative therapy, or as an option for life prolongation therapies.